Multilevel bayesian models for survival times and longitudinal patient-reported outcomes with many zeros

Journal of the American Statistical Association

Volumn 107, Issue 499, 2012, Pages 875-885

  Hatfield, Laura A ^a   Boye, Mark E ^b   Hackshaw, Michelle D ^b,c   Carlin, Bradley P ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Beta distribution; Cancer; Failure time; Random effects model; Repeated measures; Weibull distribution

Indexed keywords

EID: 84864645579     PISSN: 01621459     EISSN: 1537274X     Source Type: Journal    
DOI: 10.1080/01621459.2012.664517     Document Type: Article

References (36)

1. Berman, D., and Crump, K. (2003), "Technical Support Document for a Protocol to Assess Asbestos-Related Risk: Final Draft," Technical Report, United States Environmental Protection Agency.[876]
2. Bottomley, A., Coens, C., Efficace, F., Gaafar, R., Manegold, C., Burgers, S., Vincent, M., Legrand, C., van Meerbeeck, J., and Eort Cncic. (2007), "Symptoms and Patient-Reported Well-Being: Do They Predict Survival in Malignant PleuralMesothelioma? A Prognostic Factor Analysis of EORTCNCIC 08983: Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma," Journal of Clinical Oncology, 25, 5770-5776.[877]
3. Brooks, S., and Gelman, A. (1997), "General Methods for Monitoring Convergence of Iterative Simulations," Journal of Computational and Graphical Statistics, 7, 434-455.[879]
4. Cook, D., Kieschnick, R., andMcCullough, B. (2008), "Regression Analysis of Proportions in Finance With Self Selection," Journal of Empirical Finance, 15, 860-867.[877]
5. Czado, C., and Santner, T. (1992), "The Effect of Link Misspecification on Binary Regression Inference," Journal of Statistical Planning and Inference, 33, 213-231.[876]
6. Eli Lilly and Company. (2010), "Alimta Prescribing Information," Available at http://pi.lilly.com/us/alimta-pi.pdf [876]
7. Eli Lilly and Company (2011), "Information for Patients and Caregivers, Alimta R(Pemetrexed for Injection)," available at http://pi.lilly.com/us/alimta-ppi.pdf [879]
8. Fairclough, D. (2004), "Patient Reported Outcomes as Endpoints in Medical Research," Statistical Methods in Medical Research, 13, 115-138. [884]
9. Galateau-Sallé, F. (2006), "Epidemiology of Mesothelioma," in Pathology of Malignant Mesothelioma, ed. F. Galateau-Sall ́e, London: Springer, pp. 1-10.[876]
10. Ghosh, P., and Albert, P. (2009), "A Bayesian Analysis for Longitudinal Semicontinuous Data With an Application to an Acupunture Clinical Trial," Computational Statistics and Data Analysis, 53, 699-706.[875]
11. Ghosh, S., Gelfand, A., Clark, J., and Zhu, K. (2011), "The k-ZIG: FlexibleModeling for Zero-Inflated Counts," Technical Report, Department of Statistics, Duke University.[876]
12. Hanson, T., Branscum, A., and Johnson, W. (2011), "Predictive Comparison of Joint Longitudinal-Survival Modeling: ACase Study Illustrating Competing Approaches," Lifetime Data Analysis, 17, 3-28.[875]
13. Hatfield, L., Hodges, J., and Carlin, B. (2011), "Bayesian Learning in Hierarchical Joint Models," Technical Report, Division of Biostatistics, School of Public Health, University of Minnesota.[884]
14. Hollen, P., Gralla, R., Liepa, A., Symanowski, J., and Rusthoven, J. (2006), "Measuring Quality of Life in Patients With Pleural Mesothelioma Using a ModifiedVersion of the Lung Cancer Symptom Scale (LCSS): Psychometric Properties of the LCSS-Meso," Supportive Care in Cancer, 14, 11-21.[876]
15. Ibrahim, J., Chen, M.-H., and Sinha, D. (2002), Bayesian Survival Analysis, New York: Springer-Verlag.[884]
16. Lachenbruch, P. (2002), "Analysis of DataWith Excess Zeros," Statistical Methods in Medical Research, 11, 297-302.[875]
17. Laffler, M. (2009, September 16), "FDA Will Revisit Appropriate use of PFS Endpoints at Advisory Committee," The Pink Sheet Daily, Article No.14090916003. [877]
18. Lipscomb, J., Reeve, B., Clauser, S., Abrams, J., Bruner, D., Burke, L., Denicoff, A., Ganz, P., Gondek, K., Minasian, J., OMara, A., Revicki, D., Rock, E., Rowland, J., Sgambati, M., and Trimble, E. (2007), "Patient-Reported Outcomes Assessment in Cancer Trials: Taking Stock, Moving Forward," Journal of Clinical Oncology, 25, 5133-5140.[877]
19. Lu, C., and Meeker, W. (1993), "Using Degradation Measures to Estimate a Time-to-Failure Distribution," Technometrics, 35, 161-174. [875]
20. Lunn, D. (2003), "Win BUGS Development Interface (WBDev)," ISBA Bulletin, 10, 10-11. [879]
21. Neuhaus, J. (1999), "Bias and Efficiency Loss Due to Misclassified Responses in Binary Regression," Biometrika, 86, 843-855.[876]
22. Niyikiza, C., Baker, S., Seitz, D., Walling, J., Nelson, K., Rusthoven, J., Stabler, S., Paoletti, P., Calvert, A., and Allen, R. (2002), "Homocysteine and Methylmalonic Acid: Markers to Predict and Avoid Toxicity From Pemetrexed Therapy," Molecular Cancer Therapeutics, 1, 545-552.[877]
23. Pregibon, D. (1980), "Goodness of Link Tests for Generalized Linear Models," Applied Statistics, 29, 15-24. [876]
24. Ray, M., and Kindler, H. L. (2009), "Malignant Pleural Mesothelioma," Chest, 136, 888-896.
25. Rizipoulos, D., Verbeke, G., and Molenberghs, G. (2008), "Shared Parameter Models Under Random Effects Misspecification," Biometrika, 95, 63-74. [878]
26. Rizopoulos, D., Verbeke, G., Lesaffre, E., and Vanrenterghem, Y. (2008), "A Two-Part Joint Model for the Analysis of Survival and Longitudinal BinaryData With Excess Zeros," Biometrics, 64, 611-619.[876]
27. Rock, E., Kennedy, D., Furness, M., Pierce, W., Pazdur, R., andBurke, L. (2007), "Patient-Reported Outcomes Supporting Anticancer Product Approvals," Journal of Clinical Oncology, 25, 5094-5099. [877]
28. Rusch, V. (1995), "A Proposed New International TNMStaging System forMalignant PleuralMesothelioma. From the InternationalMesothelioma Interest Group," Chest, 108, 1122-1128. [877]
29. Spiegelhalter, D., Thomas, A., Best, N., and Lunn, D. (2004), Win BUGS User Manual, Version 1.4 ed., Cambridge: MRC Biostatistics Unit, Institutes of Public Health. [879]
30. Sturtz, S., Ligges, U., and Gelman, A. (2005), "R2WinBUGS: A Package for Running Win BUGS From R," Journal of Statistical Software, 12, 1-16.[879]
31. Tsiatis, A., and Davidian, M. (2004), "Joint Modeling of Longitudinal and Time-to-Event Data: An Overview," Statistica Sinica, 14, 809-834.[875]
32. U.S. Food and Drug Administration (2004), "Alimta Label and Approval History, NDA 021677," available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm [876]
33. Vogelzang, N., Rusthoven, J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., Niyikiza, C., and Paoletti, P. (2003), "Phase III Study of Pemetrexed in CombinationWith Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma," Journal of Clinical Oncology, 21, 2636-2644. [876,884]
34. Wagner, J., Sleggs, C., and Marchand, P. (1960), "Diffuse PleuralMesothelioma andAsbestos Exposure in the NorthWesternCape Province," British Journalof Industrial Medicine, 17(4), 260-271.[876]
35. Wang, X., and Dey, D. (2010), "Generalized Extreme Value Regression for Binary Response Data: An Application to B2B Electronic Payments System Adoption," The Annals of Applied Statistics, 4, 2000-2003.[876]
36. Zucali, P., De Vincenzo, F., Simonelli, M., and Santoro, A. (2009), "Future Developments in the Management of Malignant Pleural Mesothelioma," Expert Review of Anticancer Therapy, 9, 453-467. [876]